BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11173547)

  • 1. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
    Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
    Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S
    Jpn J Cancer Res; 2000 Apr; 91(4):424-32. PubMed ID: 10804291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
    Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
    Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
    Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
    Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
    Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
    Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
    Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
    Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
    Galanis E; Goldberg R; Reid J; Atherton P; Sloan J; Pitot H; Rubin J; Adjei AA; Burch P; Safgren SL; Witzig TE; Ames MM; Erlichman C
    Ann Oncol; 2001 May; 12(5):701-7. PubMed ID: 11432631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
    Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
    Akutsu M; Kano Y; Tsunoda S; Suzuki K; Yazawa Y; Miura Y
    Eur J Cancer; 1995 Dec; 31A(13-14):2341-6. PubMed ID: 8652267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
    Jackman AL; Kimbell R; Ford HE
    Eur J Cancer; 1999 Mar; 35 Suppl 1():S3-8. PubMed ID: 10645207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
    Sobrero A; Romanini A; Russello O; Nicolin A; Rosso R; Bertino JR
    Eur J Cancer Clin Oncol; 1989 Jun; 25(6):977-82. PubMed ID: 2526736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.